Endogenous GABA modulates histamine release from the anterior hypothalamus of the rat.
Using a microdialysis method, we investigated the effects of the nipecotic acid-induced increase in content of endogenous GABA on in vivo release of histamine from the anterior hypothalamus (AHy) of urethane-anesthetized rats. Nipecotic acid (0.5 mM), an inhibitor of GABA uptake, decreased histamine release to approximately 60% of the basal level. This effect was partially antagonized by picrotoxin (0.1 mM), an antagonist of GABAA receptors, or phaclofen (0.1 mM), an antagonist of GABAB receptors. These results suggest that histamine release is modulated by endogenous GABA through both GABAA and GABAB receptors. When the tuberomammillary nucleus, where the cell bodies of the histaminergic neurons are localized, was stimulated electrically, the evoked release of histamine from the nerve terminals in the AHy was significantly enhanced by phaclofen, suggesting that GABAB receptors may be located on the histaminergic nerve terminals and modulate histamine release presynaptically. On the other hand, picrotoxin caused an increase in histamine release to approximately 170% of the basal level, and this increase was diminished by coinfusion with D(-)-2-amino-5-phosphonopentanoic acid (0.1 mM), an antagonist of NMDA receptors. Previously, we demonstrated tonic control of histamine release by glutamate mediated through NMDA receptors located on the histaminergic terminals in the AHy. These results suggest the possible localization of GABAA receptors on glutamatergic nerve terminals and that the receptors may regulate the basal release of histamine indirectly.
Okakura-Mochizuki
K
K
Department of Molecular Physiology, Faculty of Medicine, Osaka University, Osaka, Japan.
Mochizuki
T
T
Yamamoto
Y
Y
Horii
A
A
Yamatodani
A
A
D015763:2-Amino-5-phosphonovalerate / Q000494:pharmacology; D000818:Animals; D004558:Electric Stimulation; D018691:Excitatory Amino Acid Antagonists / Q000494:pharmacology; D018756:GABA Antagonists / Q000494:pharmacology; D058785:GABA-A Receptor Agonists; D058786:GABA-B Receptor Agonists; D006636:Histamine Release / Q000187:drug effects*; D007032:Hypothalamus, Anterior / Q000166:cytology / Q000378:metabolism*; D008297:Male; D017551:Microdialysis; D009474:Neurons / Q000378:metabolism / Q000648:ultrastructure; D009557:Nipecotic Acids / Q000494:pharmacology; D010852:Picrotoxin / Q000494:pharmacology; D017729:Presynaptic Terminals / Q000187:drug effects / Q000378:metabolism; D011392:Proline / Q000031:analogs & derivatives*; D051381:Rats; D017208:Rats, Wistar; D005680:gamma-Aminobutyric Acid / Q000494:pharmacology*
D015763:2-Amino-5-phosphonovalerate; D018691:Excitatory Amino Acid Antagonists; D018756:GABA Antagonists; D058785:GABA-A Receptor Agonists; D058786:GABA-B Receptor Agonists; D009557:Nipecotic Acids; D010852:Picrotoxin; D011392:Proline; D005680:gamma-Aminobutyric Acid; C030278:nipecotic acid; C010983:homoproline